Webinars, Pharmaceutical

Looking Beyond Component Quality for Sensitive Biologic Injectables

26 Oct 2026

This webinar looks beyond the quality of individual closure components to explore what makes a primary packaging strategy successful for sensitive biologic injectables. Michel Pittet, Camille Dumas and Marco Milan from UCB will join Aptar Pharma’s Estelle Verger and Nicolas Voisin to discuss how upstream quality, contamination control and supply resilience can support better primary packaging decisions for injectable therapies.

Thursday, 19 November 2026

Register for 10:00 AM CET Session

Register for 4:00 PM CET Session

By: Michel Pittet (Head of Primary Packaging Management, UCB) Camille Dumas (Head of Packaging Procurement, UCB) Marco Milan (Primary Packaging Management Projects Lead, UCB) Estelle Verger (Global Business Development Director, Aptar Pharma) Nicolas Voisin (Global Quality Senior Director, Aptar Pharma)
Share
26 Oct 2026
Beyond Component Quality: A 360° Dialogue on Primary Packaging for Sensitive Biologic Injectables. Webinar, 19 November 2026.

Why attend?

Primary packaging decisions for sensitive biologic injectables go beyond the technical performance of individual elastomeric closure solutions, such as vial stoppers and pre-filled syringe plungers. Consistency, drug product compatibility and continuity of supply can affect the drug product, manufacturing operations and ultimately the patient.

In this 360° dialogue, experts from UCB and Aptar Pharma bring the drug manufacturer and primary packaging perspectives to the same table. They will explore how upstream quality, contamination control, platform strategies, multisourcing and packaging flexibility can strengthen performance and supply resilience across different injectable products and manufacturing environments.

Participants will gain a practical framework for evaluating primary packaging closure components and partners, identifying potential gaps and aligning quality, technical and supply requirements earlier in the product lifecycle.

What Participants Will Learn

  • What to consider when selecting elastomeric closure solutions for sensitive biologic injectables, and how these considerations can guide packaging decisions across injectable therapies.
  • How to evaluate primary packaging solutions and partners using a 360° framework connecting component performance, upstream quality, platform fit, flexibility and supply resilience.
  • Which questions to ask from pharmaceutical and primary packaging perspectives to identify quality, technical and supply risks earlier in packaging selection and qualification.